Transcriptional regulation of metastasis-related genes in human melanoma

Clinical and Experimental Metastasis

Volumn 20, Issue 3, 2003, Pages 251-263

  Nyormoi, Okot ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AP 2; Gene expression; Malignant melanoma; Metastasis; Transcription factor

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MUCIN; MUCIN MUC18; PROTEIN BCL 2; PROTEIN P21; PROTEINASE ACTIVATED RECEPTOR 1; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR; THROMBIN RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ANIMAL CELL; CANCER GROWTH; CARCINOGENICITY; CELL SURVIVAL; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE LOSS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NEVUS; NONHUMAN; NUDE MOUSE; ONCOGENE NEU; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; ANTIGENS, SURFACE; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; NEOPLASM METASTASIS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0037278743     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022991302172     Document Type: Review

References (133)

1. Bar-Eli M. Molecular mechanisms of melanoma metastasis. J Cell Physiol 1997; 173: 275-8.
2. Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Histol Histopathol 1998; 13: 1225-31.
3. Hall HI, Miller DR, Rogers JD et al. Update on the incidence and mortality from melanoma in the United States. J Am Acad Dermatol 1999; 40: 35-42.
4. Kopf AW, Slopek TG, Slade J et al. Techniques of cutaneous examination for the detection of skin cancer. Cancer 1995; 75: 684-90.
5. Luca M, Hunt B, Bucana CD et al. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. Melanoma Res 1993; 3: 35-41.
6. Huang S, Jean D, Luca M et al. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998; 17: 4358-69.
7. Jean D, Gershenwald JE, Huang S et al. Loss of AP-2 results in upregulation of MCAM/MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998; 273: 16501-8.
8. Jean D, Bar-Eli M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem 2000; 212: 19-28.
9. Jean D, Tellez C, Huang S et al. Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 2000; 19: 2721-30.
10. Ronai Z, Yang YM, Fuchs SY et al. ATF2 confers radiation resistance to human melanoma cells. Oncogene 1998; 16: 523-31.
11. Batlle E, Sancho E, Franci C et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2000; 2: 84-9.
12. Vachtenheim J, Novotna H, Ghanem G. Transcriptional repression of the microphthalmia gene in melanoma cells correlates with the unresponsiveness of target genes to ectopic microphthalmia-associated transcription factor. J Invest Dermatol 2001; 117: 1505-11.
13. Huang S, DeGuzman A, Bucana CD et al. Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol Ther 2000; 6: 9-17.
14. Zakut R, Perlis R, Eliyahu S et al. KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. Oncogene 1993; 8: 2221-9.
15. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Metastasis Rev 1999; 18: 377-85.
16. Lehmann JM, Riethmuller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 1989; 86: 9891-5.
17. Sers C, Kirsch K, Rothbacher U et al. Genomic organization of the melanoma-associated glycoprotein MUC18: Implications for the evolution of the immunoglobulin domains. Proc Natl Acad Sci USA 1993; 90: 8514-8.
18. Yamamoto K, Tojo A, Aoki N et al. Characterization of the promoter region of the human c-KIT protooncogene. Jpn J Cancer Res 1993; 84: 1136-44.
19. Bar-Eli M. Role of AP-2 in tumor growth and metastasis of human melanoma. Cancer Met Rev 1999; 18: 377-85.
20. Williams T, Admon A, Luscher B et al. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 1988; 2: 1557-69.
21. Gaynor RB, Muchardt C, Xia YR et al. Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p 22.3 pter. Genomics 1991; 10: 1100-2.
22. Williams T, Tjian R. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 1991; 251: 1067-71.
23. Mitchell PJ, Wang C, Tjian R. Positive and negative regulation of transcription in vitro: Enhancer-binding protein AP-2 is inhibited by SV40 antigen. Cell 1987; 50: 847-61.
24. Buettner R, Kannan P, Imhof A et al. An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation of AP-2. Mol Cell Biol 1993; 13: 4174-85.
25. Luscher B, Mitchell PJ, Williams T et al. Regulation of transcriptional factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev 1989; 3: 1507-17.
26. Mitchell PJ, Timmons PM, Hebert JM et al. Transcription factor AP-2 is expressed in neural crest cell lineages during mouse embryogenesis. Genes Dev 1991; 5: 105-19.
27. Schorle H, Meier P, Buchert M et al. Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 1996; 381: 235-8.
28. Zhang J, Hagopian-Donaldson S, Serbedzija G et al. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996; 381: 238-41.
29. Nyormoi O, Wang Z, Doan D et al. Transcription factor AP-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol Cell Biol 2001; 21: 4856-67.
30. Karjalainen JM, Kellokoski JK, Eskelinen MJ et al. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998; 16: 3584-91.
31. Huang S, Luca M, Gutman M et al. Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene 1996; 13: 2339-47.
32. Luca M, Xie S, Gutman M et al. Abnormalities in the CDKN2 (p16INK4/MTS-1) gene in human melanoma cells: Relevance to tumor growth and metastasis. Oncogene 1995; 11: 1399-402.
33. Xie S, Huang S, Luca M et al. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res 1997; 57: 2295-2303.
34. Mintz-Weber CS, Johnson JP. Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18. Loss of AP-2 is not required for MCAM expression in melanoma cell lines. J Biol Chem 2000; 275: 34672-80.
35. Xie S, Price JE, Luca M et al. Bar-Eli M. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 1997; 15: 2069-75.
36. Karlen S, Brathen LR. Role of the initiator element in the regulation of the melanoma cell adhesion molecule gene. J Invest Dermatol 2000; 115: 668-73.
37. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res 1992; 52: 3267-72.
38. Maragoudakis ME, Tsopanoglou NE, Andriopoulou P et al. Effects of thrombin/thrombosis in angiogenesis and tumour progression. Matrix Biol 2000; 19: 345-51.
39. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003; in press.
40. Gershenwald JE, Sumner W, Calderone et al. Dominant-negative transcription factor AP-2 augments melanoma tumor growth in vivo. Oncogene 2001; 20: 3363-75.
41. Liotta LA. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 1986; 46: 1-7.
42. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 2: 99-106.
43. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990; 1032: 89-118.
44. Karelina TV, Goldherg GI, Eisen AZ. Matrix metalloproteinases in blood vessel development in human fetal skin and in cutaneous tumors. J Invest Dermatol 1995; 105: 411-7.
45. Hofmann UB, Westphal JR, Waas ET et al. Matrix metalloproteinases in human melanoma cell lines and xenografts: Increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 1999; 81: 774-82.
46. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130-7.
47. Somassundaram K, Jayaraman G, Williams T et al. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Proc Natl Acad Sci USA 1996; 93: 3088-93.
48. Bosher JM, Williams T, Hurst CH. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995; 92: 744-7.
49. Gilbertson RJ, Perry RH, Kelly PJ et al. Prognostic significance of HER2 and HER4 co-expression in childhood medulloblastoma. Cancer Res 1997; 57: 3272-80.
50. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001; 14: 78-85.
51. Benson LQ, Coon MR, Krueger LM et al. Expression of MXI1, a Myc antagonist, is regulated by Spl and AP-2. J Biol Chem 1999; 274: 28794-802.
52. WAF-1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer 1999; 81: 133-40.
53. Gee JM, Robertson JF, Ellis IO et al. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 1999; 189: 514-20.
54. Ruiz M, Troncoso P, Bruns C et al. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 2001; 7: 4086-95.
55. Luca M, Huang S, Gershenwald JE et al. Expression of IL-8 by human melanoma cells upregulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997; 151: 1105-13.
56. Cowley GP, Smith ME. Cadherin expression in melanocytic naevi and malignant melanomas. Am J Pathol 1996; 179: 183-7.
57. Jiang H, Lin J, Su ZZ et al. The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 1995; 10: 1855-64.
58. Vidal MJ, Loganzo F Jr, de Oliveira AR et al. Mutations and defective expression of the WAF-1 p21 tumor-suppressor gene in malignant melanomas. Melanoma Res 1995; 5: 243-50.
59. Natali PG, Nicotra MR, Digiesi G et al. Expression of gp 185 HER2 in human cutaneous melanoma: Implications for experimental immunotherapeutics. Int J Cancer 1994; 56: 341-6.
60. Descheemaeker KA, Syns S, Nelles L et al. Interaction of AP-1-like, AP-2-like and SP-1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. J Biol Chem 1992; 267: 15086-91.
61. van den Oord JJ, Vandeghinste N, De Ley M et al. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145: 294-300.
62. Gille J, Swerlick RA, Caughman SW. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 1997; 16: 750-9.
63. Silins G, Grimmond S, Egerton M et al. Analysis of the promoter region of the human VEGF-related factor gene. Biochem Biophys Res Commun 1997; 230: 413-8.
64. Werner H, Stannard B, Bach MA et al. Cloning and characterization of the proximal promoter region of the rat insulin-like growth factor I (IGF-I) receptor gene. Biochem Biophys Res Commun 1990; 169: 1021-7.
65. Halaban R, Pomerantz SH, Marshall S et al. Regulation of tyrosinase in human melanocytes grown in culture. J Cell Biol 1983; 97: 480-8.
66. Halaban R, Pomerantz SH, Marshall S et al. Tyrosinase activity and abundance in Cloudman melanoma cells. Arch Biochem Biophys 1984; 230: 383-7.
67. Meyer TE, Habener JF. Cyclic adenosine 3′,5′-monophosphate response element binding protein (CREB) and related transcription-activating deoxyribonucleic acid-binding proteins. Endocr Rev 1993; 3: 269-90.
68. Lee KA, Masson N. Transcriptional regulation by CREB and its relatives. Biochim Biophys Act 1993; 3: 221-33.
69. Lemaigre FP, Ace CI, Green MR. The cAMP response element binding protein, CREB, is a potent inhibitor of diverse transcriptional activators. Nucleic Acids Res 1993; 21: 2907-11.
70. Hurst HC, Totty NF, Jones NC. Identification and functional characterization of the cellular activating transcription factor 43 (ATF-43) protein. Nucleic Acids Res 1991; 19: 4601-9.
71. Rehfuss RP, Walton KM, Loriaux MM et al. The cAMP-regulated enhancer-binding protein ATF-1 activates transcription in response to cAMP-dependent protein kinase. J Biol Chem 1991; 266: 18431-4.
72. Ruthberg SE, Goldstein IM, Yang YM et al. Expression and transcriptional activity of AP-1, CRE, and URE binding proteins in B 16 mouse melanoma subclones. Mol Carcinog 1994; 10: 82-7.
73. Bohm M. Moellmann G, Cheng E. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ 1995; 6: 291-302.
74. Walton KM, Rehfuss RP, Chriva JC et al. A dominant repressor of cyclic adenosine 3′,5′-monophosphate (cAMP)-regulated enhancer-binding protein activity inhibits the cAMP-mediated induction of the somatostain promoter in vivo. Mol Endocrinol 1992; 6: 647-55.
75. Woloshin PI, Walton KM, Rehfuss RP et al. 3′,5′-Cyclic adenosine monophosphate-regulated enhancer binding (CREB) activity is required for normal growth and differentiated phenotype in the FRTL5 thyroid follicular cell line. Mol Endocrinol 1992; 6: 1725-33.
76. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990; 265: 11077-82.
77. 2+ concentration. Arch Biochem Biophys 1996; 269: 365-70.
78. McConkey DJ, Orrenius S. The role of calcium in the regulation of apoptosis. J Leukoc Biol 1996; 59: 775-83.
79. Gonzalez CA, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 1989; 59: 675-80.
80. Sheng M, Thompson MA, Greenberg ME. CREB: A Ca(2+)-regulated transcription factor phosphorylated by calmodulin-dependent kinases. Science 1991; 252: 1427-30.
81. Thastrup O., Cullen PJ, Drobak BK et al. Thapsigargin, a tumor promoter, discharges intracellalar Ca(2+) stores by specific inhibition of the endoplasmic reticulum Ca(2+)-ATPase. Proc Natl Acad Sci USA 1990; 87: 2466-70.
82. Muthukkumar S, Nair P, Sells SF et al. Role of EGR-1 in thapsigargin-inducible apoptosis in the melanoma cell line A375-C6. Mol Cell Biol 1995; 15: 6262-72.
83. Jean D, Harbison M, McConkey DJ et al. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem 1998; 273: 24884-90.
84. Raag R, Whitlow M. Single-chain Fvs. FASEB J 1995; 1: 73-80.
85. Winter G, Milstein C. Man-made antibodies. Nature 1991; 349: 293-299.
86. Orten DJ, Strawhecker JM, Sanderson SD et al. Differential effects of monoclonal antibodies on activating transcription factor-1 and cAMP response element binding protein interactions with DNA. J Biol Chem 1994; 51: 32254-3263.
87. Jean D, Bar-Eli M. Targeting the ATF-1/CREB transcription factors by single chain Fv fragment in human melanoma: Potential modality for cancer therapy. Crit Rev Immunol 2001; 21: 275-86.
88. Medrano EE, Farooqui JZ, Boissy RE et al. Chronic growth stimulation of human adult melanocytes by inflammatory mediators in vitro: Implications for nevus formation and initial steps in melanocyte oncogenesis. Proc Natl Acad Sci USA 1993; 90: 1790-4.
89. Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene 2002; 21: 1000-8.
90. Kim SJ, Wagner S, Liu F et al. Retinoblastoma gene product activates expression of the human TGF-beta 2 gene through transcription factor ATF-2. Nature 1992; 358: 331-4.
91. van Dam H, Duyndam M, Rottier R et al. Heterodimer formation of c-Jun and ATF-2 is responsible for induction of c-Jun by the 243 amino acid adenovirus E1A protein. EMBO J 1993; 12: 479-87.
92. Gupta S, Campbell D, Derijard B et al. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995; 267: 389-93.
93. Kaszubska W, Hooft van Huijsduijnen R, Ghersa P et al. Cyclic AMP-independent ATF family members interact with NF-kappa B and function in the activation of the E-selectin promoter in response to cytokines. Mol Cell Biol 1993; 13: 7180-90.
94. Shimizu M, Nomura Y, Suzuki H et al. Activation of the rat cyclin A promoter by ATF2 and Jun family members and its suppression by ATF4. Exp Cell Res 1998; 239: 93-103.
95. Tsai EY, Jain J, Pesavento PA et al. Tumor necrosis factor alpha gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol Cell Biol 1996; 16: 459-67.
96. Ivanov VN, Kehrl JH, Ronai Z. Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene 2000; 19: 933-42.
97. Ivanov VN, Ronai Z. Down-regulation of tumor necrosis factor alpha expression by activating transcription factor 2 increases UVC-induced apoptosis of late-stage melanoma cells. J Biol Chem 1999; 274: 14079-89.
98. Bhoumik A, Ivanov V, Ronai Z. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment. Clin Cancer Res 2001; 7: 331-42.
99. Ivanov VN, Fodstad O, Ronai Z. Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNFalpha and suppression of NF-kappaB activities. Oncogene 2001; 20: 2243-53.
100. Danen EH, de Vries TJ, Morandini R et al. E-cadherin expression in human melanoma. Melanoma Res 1996; 6: 127-31.
101. Hsu MY, Meier FE, Nesbit M et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000; 156: 1515-25.
102. Berx G, Cleton-Jansen AM, Nollet F et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14: 6107-15.
103. Oda T, Kanai Y, Oyama T et al. E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci USA 1994; 91: 1858-62.
104. Cano A, Perez-Moreno MA, Rodrigo I et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2: 76-83.
105. Poser I, Dominguez D, de Herreros AG et al. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor snail. J Biol Chem 2001; 276: 24661-6.
106. Gruss C Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001; 13: 117-23.
107. Sefton M, Sanchez S, Nieto MA. Conserved and divergent roles for members of the Snail family of transcription factors in the chick and mouse embryo. Development 1998; 125: 3111-21.
108. Atchley WR, Fitch WM. A natural classification of the basic helix-loop-helix class of transcription factors. Proc Natl Acad Sci USA 1997; 94: 5172-6.
109. Paznekas WA, Okajima K, Schertzer M et al. Genomic organization, expression, and chromosome location of the human SNAIL gene (SNAIl) and a related processed pseudogene (SNAIlP). Genomics 1999; 62: 42-9.
110. Hemavathy K, Guru SC, Harris J et al. Human Slug is a repressor that localizes to sites of active transcription. Mol Cell Biol 2000; 20: 5087-95.
111. Yasumoto K, Mahalingam H, Suzuki H et al. Transcriptional activation of the melanocyte-specific genes by the human homolog of the mouse Microphthalmia protein. J Biochem (Tokyo) 1995; 118: 874-81.
112. Hughes AE, Newton VE, Liu XZ et al. A gene for Waardenburg syndrome type 2 maps close to the human homologue of the microphthalmia gene at chromosome 3p12-p14.1. Nat Genet 1994; 7: 509-12.
113. Tachibana M, Perez-Jurado LA, Nakayama A et al. Cloning of MITF, the human homolog of the mouse microphthalmia gene and assignment to chromosome 3p14.1- p12.3. Hum Mol Genet 1994; 3: 553-7.
114. Udono T, Yasumoto K, Takeda K et al. Structural organization of the human microphthalmia-associated transcription factor gene containing four alternative promoters. Biochim Biophys Acta 2000; 1491: 205-19.
115. Shibahara S, Takeda K, Yasumoto K et al. Microphthalmia-associated transcription factor (MITF): Multiplicity in structure, function, and regulation. J Investig Dermatol Symp Proc 2001; 6: 99-104.
116. Hornyak TJ, Hayes DJ, Chiu Ly et al. Transcription factors in melanocyte development: Distinct roles for Pax-3 and Mitf. Mech Dev 2001; 101: 47-59.
117. Carreira S, Liu B, Goding CR. The gene encoding the T-box factor Tbx2 is a target for the microphthalmia-associated transcription factor in melanocytes. J Biol Chem 2000; 275: 21920-7.
118. Fang, D, Setaluri, V. Role of microphthalmia transcription factor in regulation of melanocyte differentiation marker TRP-1. Biochem Biophys Res Commun 199; 256: 657-63.
119. King R, Weilbaecher KN, McGill G et al. Microphthalmia transcription factor. A sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999; 155: 731-8.
120. Salti GI, Manougian T, Farolan M et al. Microphthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000; 60: 5012-6.
121. Granter SR, Weilbaecher KN, Quigley C et al. Microphthalmia transcription factor: not a sensitive or specific marker for the diagnosis of desmoplastic melanoma and spindle cell (non-desmoplastic) melanoma. Am J Dermatopathol 2001; 23: 185-9.
122. Busam KJ, Iversen K, Coplan KC et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197-204.
123. Galibert MD, Yavuzer U, Dexter TJ et al. Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J Biol Chem 1999; 274: 26894-900.
124. Vachtenheim J, Novotna H. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol (Noisy-le-grand) 1999; 45: 1075-82.
125. Khong HT, Rosenberg SA. The Waardenburg syndrome type 4 gene, SOX10, is a novel tumor-associated antigen identified in a patient with a dramatic response to immunotherapy. Cancer Res 2002; 62: 3020-3.
126. Yasumoto K, Takeda K, Saito H. Microphthalmia-associated transcription factor interacts with LEF-1, a mediator of Writ signaling. EMBO J 2002; 21: 2703-14.
127. rd Annual Meeting 2002; 43: 12.
128. Tachibana M. MITF: A stream flowing for pigment cells. Pigment Cell Res 2000; 13: 230-40.
129. Huguet C, Crepieux P, Laudet V Rel/NF-kappa B transcription factors and I kappa B inhibitors: Evolution from a unique common ancestor. Oncogene 1997; 15: 2965-74.
130. Simeonidis S, Stauber D, Chen G et al. Mechanisms by which IkappaB proteins control NF-kappaB activity. Proc Natl Acad Sci USA 1999; 96: 49-54.
131. Sharma HW, Narayanan R. The NF-kappaB transcription factor in oncogenesis. Anticancer Res 1996; 16: 589-96.
132. McNulty SE, Tohidian NB, Meyskens FL Jr. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res 2001; 14: 456-65.
133. Duffey DC, Chen Z, Dong G et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 1999; 59: 3468-74.